Profilaxis de enfermedad tromboembólica en pacientes médicos hospitalizados

Autores/as

  • Andrés Aizman Sevilla Departamento de Medicina Interna. Facultad de Medicina. Pontificia Universidad Católica de Chile.
  • Eduardo Abbott Departamento de Medicina Interna. Facultad de Medicina. Pontificia Universidad Católica de Chile.
  • Luis Rojas Departamento de Medicina Interna. Facultad de Medicina. Pontificia Universidad Católica de Chile.

Palabras clave:

Anticoagulants, Pulmonary embolism, Venous thromboembolism

Resumen

Thromboembolic disease is the main preventable cause of in-hospital death. Approximately 10% of nosocomial deaths are attributable to pulmonary embolism and in most cases, the diagnosis is not suspected before the autopsy. There are cost effective measures to decrease the incidence of thromboembolic disease. Pharmacological prophylaxis decreases the incidence of deep venous thrombosis by 65% and the incidence of pulmonary embolism by 35 to 55%. Despite this data and the presence of clinical guidelines, prophylaxis of thromboembolic disease is used only in 40% of medical patients and in 65% of surgical patients with recommended indications. We will review the evidence that supports the use of thromboprophylaxis and the different strategies that can increase the compliance of physicians with its use. A protocol implemented in our institution is also proposed.  

Publicado

2011-08-30

Cómo citar

Aizman Sevilla, A., Abbott, E., & Rojas, L. (2011). Profilaxis de enfermedad tromboembólica en pacientes médicos hospitalizados. Revista Médica De Chile, 139(9). Recuperado a partir de https://mail.revistamedicadechile.cl/index.php/rmedica/article/view/951

Número

Sección

Artículos de revisión

Artículos más leídos del mismo autor/a